Chronic coronary syndrome (CCS) is a newly described classification devised by the European Society of Cardiology (ESC) 2019 to replace the term "Stable Coronary Artery Disease (CAD). The main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical, pharmacological, and pathophysiological entities. Using this new term, the disease atherosclerosis manifests as CAD is categorized into Acute Coronary Syndrome (ACS) and CCS. The main focus of introducing the concept of CCS is on the fact that CAD is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases. Dyslipidemia is recognized as a prominent risk factor for cardiovascular (CV) disease. It is characterized by an elevation of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or triglycerides (TG) and reduced serum high-density lipoprotein cholesterol (HDL-C) concentration . Genetically determined and metabolically induced disturbances in lipid metabolism, as manifested in several types of dyslipidemia, have been shown to be causally related to the development of coronary artery disease (CAD). A diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events. Independent predictors of recurrent CVD events or death include age, smoking, hypertension (HTN), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of medications recommended by current treatment guidelines.
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: August 1, 2021
- Diagnostic Test: lipid profile test .
- Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
Arms, Groups and Cohorts
- Ischemic heart disease patients .
- Study of lipid profile of patients with chronic coronary syndromes who recieve drugs of anti hyperlipidemia at the cardiology clinic of sohag university hospital.
Clinical Trial Outcome Measures
- Dyslipidemia in chronic coronary syndrome
- Time Frame: one year
- Pattern of dyslipidemia among patients with chronic coronary syndromes at sohag university hospital.
Participating in This Clinical Trial
- All patients have chronic coronary disease at Sohag University hospital who recieve drugs of anti hyperlipidemia . Exclusion Criteria:
- Patients with first attack of acute coronary syndrome . – Young patients <18 years . – Old patients >65 years.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Sohag University
- Provider of Information About this Clinical Study
- Principal Investigator: Islam Mohamed Farrag, resident doctor at internal medicine department sohag university hospital – Sohag University
- Overall Contact(s)
- Islam M Farrag, resident, 01092029333, firstname.lastname@example.org
Darroudi S, Saberi-Karimian M, Tayefi M, Arekhi S, Motamedzadeh Torghabeh A, Seyedzadeh Sani SMR, Moohebati M, Heidari-Bakavoli A, Ebrahimi M, Azarpajouh MR, Safarian M, A Ferns G, Esmaeili H, Parizadeh MR, Mokhber N, Mahdizadeh A, Mahmoudi AA, Sahebkar AH, Ghayour-Mobarhan M. Prevalence of combined and noncombined dyslipidemia in an Iranian population. J Clin Lab Anal. 2018 Oct;32(8):e22579. doi: 10.1002/jcla.22579. Epub 2018 Jun 21.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4242.
Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):221-230. doi: 10.1016/j.jcmg.2017.01.029. Epub 2017 Jul 25.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.